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DOI 10.1186/s13018-015-0153-4RESEARCH ARTICLE Open AccessWarfarin cessation is non-essential in patients
undergoing total knee arthroplasty—a
case-control study
Alfred Phillips1*, Michael Dan2, Nathan Schaefer1 and Raymond Randle3Abstract
Background: Warfarinised patients frequently present for total knee arthroplasty (TKA). Current practice of heparin
‘bridging’ is potentially cumbersome and hazardous. The research question is if cessation of warfarin is necessary
for TKA.
Methods: The study design was a retrospective case–control series of 61 warfarinised patients and 61 control
patients undergoing TKA. TKA was performed by the senior author using a medial parapatellar approach without
tourniquet. The target perioperative international normalised ratio (INR) for warfarinised patients was 2–2.2. Primary
outcomes were changes in haemoglobin, transfusion requirements and complication rates.
Results: There was no statistically significant difference between control and warfarin group in mean perioperative
Hb (g/L) (pre-op 140 vs 141, day 0 115 vs 115, day 1 108 vs 111, P = 0.63), transfusion rates (14.75% vs 9.83%,
P = 0.58), total complication rate (9.8% vs 9.8%, P = 0.75), demographics, range of motion or length of stay. There
was a statistically significant higher use of the re-infusion drain in the warfarinised group (47.5% vs 24.6%, P = 0.014).
Conclusion: This study supports the hypothesis that warfarin cessation is non-essential in patients undergoing
TKA. This data is applicable to a patient group using re-infusion drains. Limitations of this study are typical of a small
non-controlled observational study.
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Total Knee arthroplasty (TKA) is a reliable treatment for
end-stage arthritis. Osteoarthritis is the main aetiology
of arthritis requiring TKA [1]. The incidence of osteo-
arthritis increases with age as do the relative comorbidi-
ties of the patient [2]. Common comorbidities include
atrial fibrillation, venous thrombosis and valve replace-
ment and these commonly require anticoagulation ther-
apy, traditionally warfarin [3]. The Australian National
Joint registry data demonstrates a 4.1% increase in TKA
in 2012 from 2011 and a 92.4% increase since 2003 [1].
This is in keeping with a worldwide trend [4,5]. With an
ageing population and a corresponding increase in the
incidence of TKA, it is safe to assume an increasing* Correspondence: alfphillips@gmail.com
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unless otherwise stated.proportion of patients who present for TKA will be on
warfarin.
Warfarin exerts its anticoagulant affect as a vitamin K
antagonist that inhibits clotting factors 2, 7, 9 and 10.
This results in increased prothrombin time via impaired
formation of fibrin. Conversely, proteins C and S are in-
hibited, which provides an initial pro-thrombotic effect.
Warfarin is variably metabolised by the liver subject to
patient factors such as genetics, diet and medications.
The therapeutic window of warfarin is monitored via the
international normalised ratio (INR). It has a half life of
approximately 36 hours [6].
To manage the increased bleeding risk in patients
undergoing TKA, warfarin is traditionally stopped 5 days
pre-operatively. Patients are then assessed into low- and
high-risk categories, with bridging anticoagulation in the
form of low molecular weight heparin or unfractionated
heparin recommended for higher risk patients [7].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with a 1%–3% incidence of cerebrovascular events in
specific populations of patients, resulting in significant
morbidity and mortality [8,9]. There is also the concern
that a rebound hypercoagulability on cessation can lead to
increased risk of thrombotic events due to re-initiating
warfarin [10,11]. Bridging therapy increases post-operative
stay and healthcare costs as warfarin is restarted [12]. Re-
cently, Simpson et al. found that bridging anticoagulation
therapy for warfarinised patients undergoing TKA was as-
sociated with an increased risk of prolonged wound drain-
age, superficial infection, deep infection, washout and
revision surgery [13].
In an effort to decrease risks and costs, studies have
explored the safety of continuing warfarin periopera-
tively [9,14-17]. Rhodes et al. [18] and Chana et al. [19]
suggest that cessation of warfarin perioperatively in pa-
tients undergoing TKA is unnecessary. These retrospect-
ive case–control studies including 38 and 24 patients in
each group, respectively, are limited by low numbers. Our
aim was to expand upon current literature and show that
warfarin can be continued safely and effectively within its
therapeutic range in patients undergoing TKA.
Methods
The study design was a retrospective observational case–
control series that required low-risk ethics approval and
relevant data was obtained from the Health Information
Services Unit. The senior author (RR) maintains lists of all
his patients undergoing procedures while on any form of
anticoagulation. The hospital reference numbers of the
patients that underwent TKA while remaining on warfarin
were used to locate charts and gather de-identified data.
Data was extracted from inpatient notes, pathology, and
operation and anaesthetic reports.
The inclusion criteria for the warfarin group of the
study were long-term warfarinised patients (minimum of
6 months duration with stable INR) who underwent
TKA by the senior author. No patients were excluded
due to increased bleeding risk, high BMI, more complex
TKA or at high risk of complications from general an-
aesthesia during the study period. Sixty one warfarinised
patients were included in the study. The target INR
range for the warfarinised group was 2–2.2 on the day of
surgery. A total of 61 age- and gender-matched control
subjects were chosen from the senior author’s booking
diary during the same time period as the study group.
The only information visible in the diary was the control
patient’s name, date of birth and hospital reference num-
ber. The control subject age range was 6 months older
or younger than the study subject. Patients were not
matched for BMI but there was no statistically signifi-
cant difference in BMI (29.7 kg/m2 for the control group
vs 30.9 kg/m2 for the warfarin group (P = 0.23). Inclusioncriteria for control subjects were age- and gender-matched
patients undergoing TKA who were not on warfarin.
The study period included a consecutive cohort of war-
farinised patients undergoing TKA from the time the se-
nior author initially used this method of perioperative
anticoagulation up the time of data collection. All warfari-
nised patients were on warfarin as lone anticoagulation.
Six control patients were on aspirin for primary preven-
tion of cardiovascular disease prior to surgery. Aspirin
was ceased in all of these patients pre-operatively. All
non-steroidal anti-inflammatory drugs were ceased 7
days pre-operatively in both study groups to optimise
renal perfusion.
All warfarinised patients received a general anaesthetic.
Control patients either received general or spinal anaes-
thetic informed by the anaesthetist and patient preference.
All 122 patients were implanted with DePuy PFC implants
between 2010 and 2013. With meticulous haemostasis, a
medial parapatellar approach was used without tourniquet
(not inflated at any stage during the procedure). All
wounds were closed in ‘water-tight’ layers with the knee
flexion with interrupted polydioxanone (PDS) and Mono-
cryl to skin. There was no use of tranexamic acid (TXA),
bipolar sealers or any other haemostatic techniques be-
sides electrocautery during surgery. This cohort of pa-
tients was from a period before TXA was in mainstream
use. All patients had re-infusion drains inserted intra-
operatively and standardised pathology collected. All
drains were removed day 1 post-operatively. All patients
were able to full weight bear immediately post-operatively
and underwent a standardised physiotherapy rehabilita-
tion protocol commencing day 1 post-operatively. The se-
nior author made all decisions regarding post-operative
transfusion using the National Health and Medical Re-
search Council (NHMRC) transfusion guidelines de-
pending on the volume of the blood loss, fluid status, Hb
concentration and the patient’s clinical condition. Pa-
tients who were symptomatically anaemic with Hb of <80
or <100 g/L in those with a documented history of end-
organ atherosclerotic disease (i.e., ischaemic heart disease,
chronic renal failure) were transfused red blood cells.
Warfarin dosing in the warfarin group was titrated
using INR in an attempt to achieve a perioperative
range of 2–2.2. The INR was checked within 48 h pre-
operatively in all warfarinised patients. Patients were
counselled pre-operatively about the effects of diet on
INR and encouraged not to make any significant changes
to their diet perioperatively. Patient diet was not formally
modified or monitored at any stage of care. Control sub-
jects were commenced on rivaroxaban (10 mg once daily)
as a lone anticoagulation agent in the immediate post-
operative period. All patients used the same mechani-
cal venous thromboembolism (VTE) prophylaxis while
inpatients.
Table 1 Frequency distribution of indications for
warfarinisation
Indication for warfarin in the study group Number (%) of
the study group
History of atrial fibrillation 33 (54.1)
Previous venous thromboembolism 17 (27.9)
Cerebrovascular accident 3 (4.9)
Myocardial infarction 2 (3.3)
Valvular heart disease 2 (3.3)
Severe peripheral vascular disease 1 (1.6)
Paroxysmal atrial arrhythmia and pacemaker 1 (1.6)
Mechanical heart valve 1 (1.6)
Ischaemic heart disease 1 (1.6)
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sessment including basic blood tests and coagulation pro-
files by the senior author. Standardised post-operative
outcome data from clinical reviews at 2 weeks, 6 weeks
and 6 months were used to assess medium-term out-
comes for all patients. The minimum length of follow-up
for the study was 6 months. This timing corresponded to
when patients were first discharged back into the care of
their local doctor. The average follow-up was 8.5 months
for the study group (range 6 to 15 months) and 9 months
for the control group (range 6 to 13 months). All out-
comes and adverse events were included up until the time
of discharge or if the patient was seen again for a related
matter on an ‘as needed’ basis.
Statistical analysis was performed using SPSS version
21 for Windows (SPSS Inc., Chicago, IL). Variables were
summarised by the mean, standard deviation (SD), 95%
confidence intervals or frequency. Chi-square tests were
used to compare categorical variables. Independent sam-
ple T tests were used to compare quantitative variables
for two groups. A repeated measures analysis of variance
(ANOVA) was performed to test the hypothesis that
warfarin is associated with different Hb levels across
time compared to controls. Statistical significance was
set at P < 0.05 for all tests. A post hoc power analysis
was performed with observed values from the data col-
lected. The sample size used in this study (n = 61 in each
group) yielded approximately 8% power to detect the ef-
fect size 0.2% as being statistically significant (P < 0.05).
This was based on a mean of 108 g/L (SE = 1.7) in con-
trols and a mean difference of ~2.6 g/L between control
and study group at day 1.Results
There was no statistically significant difference in patient
age, gender or pre- and post-operative range of motion
between the warfarin and control groups. There was no
statistically significant difference in BMI between the
two groups (29.7 kg/m2 for control group vs 30.9 kg/m2
for the warfarin group, P = 0.23). There was no statisti-
cally significant difference in surgical time between the
two groups. The mean operative time for the control
group was 56 min vs 54 min for the warfarin group (P =
0.31). The mean pre-operative INR in the warfarinised
group was 2.0 (range 1.9 to 2.3). The most common in-
dication for warfarinisation of patients in this study was
a history of atrial fibrillation and venous thrombo-
embolism shown in Table 1.
There was no statistically significant difference bet-
ween the control and warfarin group in the mean peri-
operative haemoglobin (pre-op 140 vs 141 g/L, day 0
115 vs 115 g/L, day 1 108 vs 111 g/L P = 0.63) as shown
in Figure 1.There was no statistically significant difference in total
transfusion rates (14.75% vs 9.83%, P = 0.58) as shown in
Table 2.
There was a statistically significant higher use of the
re-infusion drain in the warfarinised group (47.5% vs
24.6 %, P = 0.014) as shown in Table 3. The mean INR
for the warfarin group was 2.0 pre-operatively, 2.5 on
days 1 and 2 and 2.3 on day 3 post-operatively.
There was no statistically significant difference in the
total complication rate (9.8% vs 9.8%, P = 0.75). A war-
farinised, immunosuppressed, morbidly obese patient
with rheumatoid arthritis developed a septic TKA. Pre-
operative counselling addressed her significantly increased
risk of infection. She underwent two-stage revision and
made a full recovery with a range of motion of 0°–105°.
A warfarinised patient was re-admitted day 14 post-
operatively with a haemarthrosis secondary to a supra-
therapeutic INR of 8. The haemarthrosis was treated
conservatively with ice and elevation while his INR was
corrected. He was discharged day 3 post re-admission
and made a good recovery with a range of motion of
10°–115°.
A warfarinised patient with a history of lower gas-
trointestinal tract bleeds was re-admitted day 8 post-
operatively with malaena and Hb of 78 g/L. The patient
was transfused two units of packed red bloods cells and
four units of fresh frozen plasma. An upper endoscopy
and colonoscopy did not identify the source of bleed-
ing. The malaena resolved and the patient made a good
functional recovery with a range of motion of 3°–110°.
A warfarinised patient with long-standing mild cognitive
impairment fell out of bed during an episode of acute
confusion post-operatively. They sustained a superficial
wound dehiscence that required closure under general
anaesthetic. The wound healed well; however, poor
compliance post-operatively limited recovery, resulting
in a range of motion of 45° to 105°.
Figure 1 Perioperative trends in haemoglobin.
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disease suffered a non-ST elevated myocardial infarction
(NSTEMI) day 3 post-operatively in the setting of anal-
gesic nephropathy. The patient was treated with a GTN
infusion and PCI where they were found to have 50%
stenosis of their left anterior descending (LAD) coronary
artery. A good functional recovery achieved a range of
motion 0°–115°.
A warfarinised patient with an extensive past medical
history of cardiovascular events suffered a TIA post-
operatively. A carotid Doppler ultrasound showed a 50%–
69% carotid stenosis. The patient was treated conserva-
tively and made a good recovery with a post-operative
range of motion of 20°–105° (pre-operative ROM 20°–95°).
A control patient was readmitted 3 weeks post-
operatively with a 3-day history of malaena and haemoglo-
bin of 77 g/L. The patient underwent endoscopy and wasTable 2 Post-operative transfusion requirements
Control
group (n = 61)
Warfarin
group (n = 61)
P value








Total % of patients requiring
transfusion of PRBCs
14.75% 9.83% P = 0.58
Total number of units PRBCs
transfused
21 14found to have duodenal erosions. The patient was trans-
fused three units of packed red blood cells. The patient re-
covered well and achieved a range of motion of 5°–90°.
A control patient developed anaemia unresponsive to
a total of six units of packed red bloods cells. The pa-
tient had a history of severe peripheral vascular dis-
ease, left below-knee amputation (BKA), polymyalgia
rheumatica on oral steroids and chronic obstructive
pulmonary disease (COPD) on home oxygen. Day 7 post-
operatively, the patient underwent gastroscopy that identi-
fied distal gastritis that was treated with a proton pump
inhibitor. The patient also developed bilateral pulmo-
nary emboli on CT pulmonary angiogram at 8 weeks
post-operatively. The patient was treated with aspirin
and warfarin (with LMWH bridging). The patient had
significant hamstring spasm and compliance issues post-
operatively with a range of motion of 45°–100°. At lastTable 3 Post-operative use of re-infusion drains
Control
group (n = 61)
Study
group (n = 61)
P value










Use of re-infusion drain (%) 24.6 47.5 P = 0.014
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under anaesthesia.
A control patient suffered a superficial wound dehis-
cence while flexing their knee day 3 post-operatively.
The wound was closed under local anaesthetic and healed
well. The patient made a good functional recovery with a
range of motion at 0°–110°.
A control patient suffered a seizure in the immediate
post-operative period in the recovery suite. The patient
likely received an inadvertent intravenous dose of local
anaesthetic for a regional block by the anaesthetic team.
The patient had no hypotension or signs of decreased
cardiac output. They received 5 mg of intravenous mid-
azolam, which resulted in immediate cessation of seizure
activity. The patient was transferred to the intensive care
unit for observation and discharged to the general ortho-
paedic ward day 2 post-operatively with no long-term
sequelae. The patient made a good post-operative recov-
ery with a range of motion of 5°–110°.
A control patient developed post-operative confusion
secondary to anaemia day 3 post-operatively. The patient
had a normal CT head and a negative septic screen. They
received three units of PRBCs and had a good long-term
outcome with a range of motion of 5°–100°.
Discussion
The results of this study support the hypothesis that ces-
sation of warfarin in patients undergoing total knee
arthroplasty is not necessary. Warfarin continuation was
shown to be a safe and effective way of anticoagulating
patients perioperatively. Two other studies (Rhodes et al.
and Chana et al.) have investigated the continuation of
warfarin in patients undergoing TKA [18,19].
Rhodes et al. and Chana et al. found no increase in the
rate of haemorrhage for patients on continuous warfarin.
In our study, of 61 warfarinised patients undergoing
TKA, the mean pre-operative INR in the warfarinised
group was 2.0 with a mean increase of 0.3 by day 3 post-
operatively. The senior author designated the optimal
perioperative INR range of 2–2.2. Chana et al. reported
similar results with a mean pre-operative INR of 2.2 and
a mean change in INR of 0.4 [19]. Rhodes et al. also re-
ported a mean pre-operative INR of 2.1 and a mean
change in INR of 1.2 [18].
There was no statistically significant difference in peri-
operative haemoglobin and total complication rates be-
tween warfarinised and control patients in our study.
Both Chana et al. and Rhodes et al. also found that there
was no statistically significant difference in complication
rates in warfarinised patients undergoing TKA [18,19].
None of the warfarinised patients in our study suffered
any embolic events such as VTE or CVA.
No statistically significant difference in the transfusion
requirements of the two groups was demonstrated with9.8% of warfarinised patients and 14.8% of control pa-
tient requiring blood transfusions. Both Chana et al. and
Rhodes et al. also found that there was no statistically
significant difference in transfusion requirements in war-
farinised patients undergoing TKA [18,19].
All patients in our study had a closed suction drain
that was combined with a collection-re-infusion system
for post-operative blood recovery (Stryker CBCII). We
chose to include this data due to the oxygen carrying
capacity of the drain contents. Several studies have high-
lighted the merit of these systems in successfully de-
creasing allogenic transfusion requirements in total joint
arthroplasty [20-24]. There was a statistically significant
increase in autotransfusion requirements of warfarinised
patients in our study. This was a significant finding given
that there was no difference in perioperative Hb between
the two groups. We recommend that our data is appli-
cable to warfarinised patients undergoing TKA using a
similar drain.
In our study, warfarinised and control patients were
age- and gender-matched. Patient BMI and pre- and post-
operative range of motion was recorded. There was good
homogeneity of patient demographics between the two
groups. There was no statistically significant difference in
pre- and post-operative range of motion. The majority of
patients in our study were warfarinised for either atrial
fibrillation (AF) or previous VTE. In the setting of un-
treated AF, data from the Framingham studies has
shown a 28.2% risk of CVA over an 11-year period [25].
Warfarinised patients with a history of transient ischae-
mic attack, diabetes or ischaemic heart disease have
even greater risk of stroke when not anticoagulated
[26]. Despite these risks, the American College of Car-
diology maintain that warfarin can be ceased for up to
a week without bridging for procedures that carry a risk
of haemorrhage [27]. The group, along with most sur-
geons, advocate for individualised risk stratification
when determining the most effective form of periopera-
tive anticoagulation in this patient population [28].
A recent study by Simpson et al. has highlighted the
increased incidence of post-operative complications when
warfarinised patients are bridged with another agent for
TKA [13]. In this study, 149 patients on warfarin pre-
operatively were bridged with either low- or high-dose
unfractionated heparin, low- or high-dose low molecular
weight heparin, IV heparin or aspirin. There were signifi-
cantly higher complication rates in this patient group
compared to the control group with the bridged group at
particularly high all-cause risk [1.8, (95% CI 1.15 to 2.35),
P = 0.001]. There was also a significant higher incidence in
prolonged wound drainage (26.8% of cases vs 7.3% of
controls, P = 0.001); superficial infection (16.8% vs 3.3%,
P = 0.001); deep infection (6.0% vs 0% P = 0.001); return-
to-theatre for washout (4.7% vs 0.7%, P = 0.004) and
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tions of the study by Simpson et al. were multiple con-
tributing surgeons, the type of thromboprophylaxis in
the control group was not standardised, the use of tour-
niquets and drains was not standardised and there was
no uniform transfusion protocol. Despite these limita-
tions, the findings by Simpson et al. are in keeping with
our anecdotal experience and difficulty with bridging
warfarinised patients. This prompted the senior author
to first consider continuing his patients on warfarin perio-
peratively. There are currently two large multi-centre ran-
domised control trials PERIOP 2 and BRIDGE assessing
whether post-operative bridging reduces risk of VTE or
increases morbidity.
The limitations of this study are typical of small, non-
controlled, retrospective, observational studies. The num-
ber of warfarinised patients was low, which resulted in the
study being relatively underpowered and the statistics de-
scribed are susceptible to type II error. The recruitment of
these patients was passive and therefore difficult to in-
crease. The authors acknowledge that, despite being age-
and gender-matched, the control subjects were manually
selected from an operative diary. The senior author’s
practice does not use electronic records, which made it
difficult to overcome this issue. We also acknowledge
that complications were compared as a total complication
rate and we did not account for the severity of individual
complications. The decision to continue warfarin perio-
peratively precludes patients from undergoing spinal
anaesthesia due to the risk of epidural haematoma. The
senior author has not had to cease warfarin for any pa-
tients undergoing TKA. Despite being the largest series
of warfarinised patients undergoing TKA, our data does
not provide sufficient evidence to recommend cessation
of warfarin pre-operatively in more complex cases such
as revision surgery. We recommend that all patients with
increased but reducible perioperative risk should be me-
dically optimised. While there are no absolute contrain-
dications to general anaesthesia, valvular heart disease
is a common contraindication to regional anaesthesia
for which many patients are warfarinised. Current lite-
rature suggests that there is no increased risk of mor-
tality, cardiac complications or VTE between spinal and
general anaesthesia [29-31].
The strengths of this study are that it has a simple de-
sign and it is the largest published cohort of warfarinised
patients undergoing TKA. It was a single-centre, single-
surgeon study. All patients received the same implants
and the senior author made all clinical decisions.
Conclusion
The primary consideration for surgeons planning to per-
form TKA on chronically warfarinised patients is balan-
cing the risks of thromboembolism against post-operativecomplications. This is challenging. In an attempt to miti-
gate risk of complications, patients have traditionally
had warfarin withheld pre-operatively and bridged with
a shorter acting form of anticoagulation. This strategy
is potentially perilous for the patient and cumbersome
for the clinician. In conclusion, the authors feel that
continuation of warfarin is a safe and effective form of
perioperative anticoagulation in patients undergoing
TKA. Re-infusion drains should be used on warfari-
nised patients undergoing TKA. While acknowledging
the limitations of this study, the findings contribute to
the discrete body of literature that supports the notion
that warfarin cessation is non-essential in patients under-
going total knee arthroplasty with concomitant use of a
re-infusion drain.
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